Navigation Links
Mayo Clinic Studies Find REM Sleep Behavior Disorder is Associated with Other Features of Neurodegenerative Disorders

ROCHESTER, Minn., April 15, 2008 /PRNewswire-USNewswire/ -- Three new Mayo Clinic studies find that REM (rapid eye movement) sleep behavior disorder is associated with anxiety, apathy, lower scores in attention and executive functioning, as well as symptoms of Parkinson's disease. The findings will be presented at the American Academy of Neurology Annual Meeting in Chicago on April 15.

People who have REM sleep behavior disorder (RBD) appear to act out their dreams, which often are unpleasant and violent. Acting out is caused by a loss of normal muscle paralysis in REM sleep, the stage of sleep when dreaming occurs. A relatively uncommon condition, RBD is estimated to affect approximately 0.5 percent of the population, but occurs most frequently in older males.

"Previous studies have shown that some patients with RBD subsequently develop dementia and/or parkinsonism, which typically reflects a neurodegenerative disorder such as Lewy body dementia or Parkinson's disease," says Bradley Boeve, M.D., an author of these studies and a neurologist at Mayo Clinic. "Our knowledge on the RBD-neurodegenerative disease association is largely based on studies focused on single patients, or small groups of patients, with RBD. There are very few studies that have been carried out on RBD on a large scale. Plus, we currently aren't able to identify which patients with RBD will later develop other features of a neurodegenerative disease and which patients with RBD will not. We therefore sought to study RBD and other features commonly associated with Lewy body dementia and Parkinson's disease in a large population-based study."

Dr. Boeve and a team of Mayo Clinic physicians set out to determine whether cognitively-normal individuals with RBD have other features commonly associated with Lewy body dementia and Parkinson's disease. They identified 765 individuals, ages 70 to 89, who underwent a battery of scales and tests. Using the Mayo sleep questionnaire, a validated screening measure for RBD, researchers determined that 8 percent of these individuals had probable RBD. Twenty-one percent with probable RBD had anxiety and 11.5 percent had apathy (compared with 8 percent and 4 percent, respectively, for individuals without RBD). Those individuals with RBD had significantly lower scores on neuropsychological measures of attention and executive functioning, such as concentration, decision making, and higher-order problem solving. Additionally, researchers found that 1.8 percent of the individuals had both RBD and parkinsonism.

"There is currently no treatment to delay the onset or prevent dementia or parkinsonism in patients with RBD who are destined to develop these neurologic problems in the future," says Dr. Boeve. "Our ultimate goal is to use therapies that would delay the onset or prevent these problems from ever developing in patients who have a form of RBD that reflects an evolving neurodegenerative disease. However, much more research is needed to get to that point."

Dr. Boeve and his team will continue to study this group of patients to better understand how RBD is associated with neurodegenerative disease. Other members of the Mayo Clinic research team included Jennifer Molano, M.D., Ebru Mihci, M.D., Rosebud Roberts, M.B.Ch.B., Yonas Geda, M.D., David Knopman, M.D., Eric Tangalos, M.D., Glenn Smith, Ph.D., Robert Ivnik, Ph.D., Ruth Cha, V. Shane Pankratz, Ph.D., Michael Silber, M.B.Ch.B., Tanis Ferman, Ph.D., and Ronald Petersen, M.D., Ph.D.

To obtain the latest news releases from Mayo Clinic, go to ( is available as a resource for your health stories.

SOURCE Mayo Clinic
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Mayo Clinic Study Identifies Potential Causes of Young-Onset Dementia
2. Peregrine Researchers Present New Preclinical Data at AACR Annual Meeting Confirming Unique Anti-Tumor Mechanism of Bavituximab
3. MedImmune Advances Asthma Program with Start of a Phase 2 Trial in Europe and Australia and First U.S.-Based Clinical Trial for Antibody Targeting IL-13
4. Roche Gains Access to Important Oncology Target With Potential for Treating Major Cancers Such as Breast and Lung; First Drug Candidate in Phase I Clinical Testing
5. Phreesia Announces Clinical Initiative to Better Manage Symptoms of Parkinsons Disease
6. Senesco Expands on Recently Announced Preclinical Pancreatic Islet Data
7. Halozyme Therapeutics Presents Pre-Clinical Studies of Systemic Delivery of Pegylated rHuPH20 Enyzme in Prostate Cancer Models at American Association for Cancer Research Conference
8. Preclinical Study Presented at AACR Annual Meeting Shows Peregrines Anti-PS Immunocytokines Can Generate Protective Immune Responses in a Highly Aggressive Breast Cancer Model
9. Presentation of HeartWare Clinical Results
10. Clinically Proven Treatment Offers Help to Rosacea Sufferers
11. Preclinical Study Shows CTIs Brostallicins Cancer-Killing Ability Based on Genetic Profiling
Post Your Comments:
(Date:11/30/2015)... Nov. 30, 2015  Novartis will demonstrate the strength ... th American Society of Hematology (ASH) Annual Meeting. ... as well as supportive care, including key findings in ... cell therapies. The ASH Annual Meeting will be held ... Novartis Oncology . "We will be presenting ...
(Date:11/30/2015)... and BOSTON , November 30, 2015 ... develop potential new medicines directed at up to 10 ... --> PFE ) to research and develop ... protein-coupled receptor (GPCR) targets across multiple therapeutic areas. ... drug discovery and development company and wholly-owned subsidiary of ...
(Date:11/30/2015)... , November 30, 2015 ... or the "Company") announced today that it was informed by ... and Drug Safety (MFDS) has approved its Exablate Neuro ... --> --> Insightec,s Exablate ... treatment alternative that combines two technologies: Focused Ultrasound, which ...
Breaking Medicine Technology:
(Date:11/30/2015)... ... , ... Cycling, running, and walking are regular Sunday activities for many South ... 28, 2016. , That’s when the 7th annual ANF Group Tour de Broward ... and families at Joe DiMaggio Children’s Hospital. , The community fundraiser, sponsored ...
(Date:11/30/2015)... ... November 30, 2015 , ... ... ingredient list of its hemorrhoid ointment to its website. , “Our goal is ... people suffering from hemorrhoids. Adding the comparison chart and ingredient list allows our ...
(Date:11/30/2015)... ... November 30, 2015 , ... At Grand Dental PC, their priority is ... When you have dental problems, you need to turn to a dentist who listens ... treat your needs, a friendly dentist who counsels you on the best ways to ...
(Date:11/30/2015)... ... ... Dr. Seth D. Margulies specializes in orthodontics and is based in Perth ... the best available orthodontic experience in the area. Dr. Margulies has met all ... the branch of dentistry that specializes in the diagnosis, prevention, and treatment of dental ...
(Date:11/30/2015)... , ... November 30, 2015 , ... ... new study by UPMC and KingMed Diagnostics researchers. Their ... years found that consultation with UPMC pathologists resulted in significantly altered treatment plans ...
Breaking Medicine News(10 mins):